Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV

Article · October 2024

CITATIONS
0

READS
11

3 authors, including:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS
SEE PROFILE

Callistus Adewale Akinleye
Osun State University
111 PUBLICATIONS **588** CITATIONS
SEE PROFILE

Elite Journal of Medicine. Volume 2 Issue 10 (2024), Pp. 1-11

https://epjournals.com/journals/EJM

Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV

*Emmanuel Ifeanyi Obeagu[1], Callistus Adewale Akinleye[2] and Sussanah Henry Edoho[3]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda, ORCID: 0000-0002-4538-0161

[2]Department of Community Medicine, Osun State University, Osogbo, Nigeria, ORCID: 0000-0003-3778-3638

[3]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Chronic HIV infection poses significant challenges to immune function, often leading to a state of immune dysregulation characterized by persistent activation and depletion of CD4+ T cells. The CD4/CD8 ratio has emerged as a crucial biomarker for evaluating immune resilience in individuals living with chronic HIV. This review explores the implications of CD4/CD8 ratios in understanding immune responses, disease progression, and treatment efficacy. By examining the underlying mechanisms that influence these ratios and their prognostic value, we aim to provide insights that could inform personalized therapeutic strategies. The CD4/CD8 ratio not only reflects the balance between helper and cytotoxic T cells but also serves as an important indicator of overall immune health. A disrupted ratio, often marked by decreased CD4+ T cells relative to CD8+ T cells, is associated with worse clinical outcomes, including increased susceptibility to opportunistic infections and higher morbidity rates. Conversely, a higher CD4/CD8 ratio indicates a more favorable immune status and has been linked to better treatment responses and improved quality of life.

Keywords: *Immune resilience, CD4/CD8 ratio, HIV, immune function, T cells*

Introduction

Chronic HIV infection significantly alters the immune landscape, leading to persistent immune activation, CD4+ T cell depletion, and a compensatory increase in CD8+ T cells. These changes profoundly impact the individual's ability to respond to infections, manage co-morbidities, and

Citation: Obeagu EI, Akinleye CA, Edoho SH. Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV. Elite Journal of Medicine, 2024; 2(10): 1-11

achieve optimal health outcomes. The immune system's functionality in HIV-infected individuals is often assessed through the lens of T cell populations, particularly focusing on the CD4/CD8 ratio. This ratio reflects the balance between helper T cells, which are vital for orchestrating immune responses, and cytotoxic T cells, responsible for eliminating infected cells. Understanding the dynamics of CD4 and CD8 T cells in chronic HIV is essential for evaluating immune resilience and informing treatment strategies.[1-3] The significance of the CD4/CD8 ratio extends beyond merely serving as a marker of immune status; it encapsulates the overall functionality of the immune response in chronic HIV infection. A low CD4/CD8 ratio, indicative of a disrupted immune equilibrium, correlates with adverse clinical outcomes, including heightened susceptibility to opportunistic infections and an increased risk of non-AIDS-related morbidities. Conversely, a higher CD4/CD8 ratio suggests a more robust immune response, associated with better control of the virus and improved health outcomes. This review article aims to explore the implications of CD4/CD8 ratios in understanding immune resilience in chronic HIV infection.[4-6]

The CD4/CD8 ratio is influenced by a variety of factors, including viral load, immune activation, co-infections, and the effectiveness of antiretroviral therapy (ART). Chronic HIV infection induces a state of immune activation that can further exacerbate CD4+ T cell depletion and skew the CD4/CD8 ratio towards CD8+ T cell dominance. Additionally, co-infections with other pathogens, such as hepatitis viruses, can complicate the immune response, further impacting the CD4/CD8 balance.[7-8] Prognostically, the CD4/CD8 ratio serves as a valuable tool for predicting disease progression and treatment responses. Studies have demonstrated that individuals with a persistently low CD4/CD8 ratio are more likely to experience disease progression and poorer health outcomes. Therefore, monitoring the CD4/CD8 ratio can guide clinical decision-making, helping healthcare providers identify individuals who may benefit from intensified treatment strategies or additional immune-modulating therapies.[9-10]

The Role of CD4 and CD8 T Cells in Chronic HIV Infection

In the context of chronic HIV infection, the interplay between CD4+ and CD8+ T cells is pivotal in determining the immune response and disease progression. CD4+ T cells, also known as helper T cells, play a crucial role in coordinating the immune system's response to infections, including HIV. They facilitate the activation of other immune cells, such as B cells, which produce antibodies, and CD8+ T cells, which are responsible for directly killing infected cells. The depletion of CD4+ T cells is a hallmark of HIV infection, leading to a weakened immune system and increased susceptibility to opportunistic infections and various malignancies.[11-12] The infection of CD4+ T cells by HIV leads to their gradual depletion through a variety of mechanisms, including viral replication, immune-mediated destruction, and apoptosis. This depletion has profound implications for the host's immune function, as CD4+ T cells are essential for maintaining the overall integrity of the immune response. The progressive loss of these cells is associated with an increase in CD8+ T cells, which attempt to control the viral load. However, this compensatory increase often results in a dysfunctional CD8+ T cell population characterized by reduced proliferative capacity, altered cytokine production, and impaired cytotoxic function. The

imbalance between CD4+ and CD8+ T cells can compromise the immune response, resulting in a state of immune dysregulation.[13-15]

In chronic HIV infection, the CD8+ T cells play a dual role. While they are crucial for controlling viral replication and eliminating infected cells, their sustained activation can also lead to immune exhaustion. This phenomenon is characterized by the upregulation of inhibitory receptors such as PD-1 and Tim-3 on CD8+ T cells, limiting their ability to mount an effective response. The resulting state of immune exhaustion contributes to persistent viral reservoirs and challenges the efficacy of antiretroviral therapy (ART). Thus, the balance and functional status of CD4+ and CD8+ T cells are fundamental to understanding the immune dynamics in chronic HIV infection.[16-17] Moreover, the CD4/CD8 T cell ratio serves as a valuable marker for assessing immune health in individuals living with HIV. A lower CD4/CD8 ratio is indicative of an impaired immune response and is associated with worse clinical outcomes, including increased rates of opportunistic infections and comorbidities. Conversely, a higher CD4/CD8 ratio suggests a more favorable immune status, reflecting the presence of functional CD4+ T cells capable of orchestrating robust immune responses. Monitoring this ratio can thus provide insights into the immune resilience of individuals living with chronic HIV and help guide treatment decisions.[18-19]

CD4/CD8 Ratio as a Biomarker of Immune Resilience

The CD4/CD8 ratio is increasingly recognized as a valuable biomarker for assessing immune resilience in individuals living with chronic HIV infection. This ratio reflects the balance between CD4+ T cells, which are crucial for orchestrating the immune response, and CD8+ T cells, which are primarily responsible for cytotoxic activity against infected cells. A healthy immune system typically maintains a higher CD4/CD8 ratio, indicating robust immune functionality. In the context of HIV, alterations in this ratio can provide insights into the state of the immune system, guiding clinical management and therapeutic interventions.[20-21] A low CD4/CD8 ratio is often indicative of immune dysregulation and has been associated with worse clinical outcomes in HIV-infected individuals. This disruption can occur due to the depletion of CD4+ T cells, a hallmark of HIV infection, which reduces the overall capacity of the immune system to respond effectively to pathogens. The consequent rise in CD8+ T cell numbers, in the absence of sufficient CD4+ T cell support, may lead to functional exhaustion of the cytotoxic T cell population. This scenario not only heightens the risk of opportunistic infections but also compromises the effectiveness of antiretroviral therapy (ART), as the immune system struggles to control the viral load.[22-23]

Conversely, a higher CD4/CD8 ratio is often associated with improved immune competence and better health outcomes. Individuals with a favorable CD4/CD8 ratio are more likely to exhibit effective immune responses, maintain lower viral loads, and experience a reduced incidence of opportunistic infections and non-AIDS-related comorbidities. Thus, monitoring the CD4/CD8 ratio can serve as a useful tool for evaluating immune resilience and predicting disease progression. Clinicians can utilize this information to tailor treatment strategies, focusing on enhancing CD4+ T cell recovery and maintaining a balanced immune response.[24-25] Furthermore, the CD4/CD8 ratio is influenced by various factors, including viral load, immune activation, and co-infections. High levels of HIV viral load contribute to increased immune activation, leading to further depletion of

CD4+ T cells and skewing the CD4/CD8 balance. Additionally, co-infections with other pathogens can complicate the immune landscape, impacting the functionality of both CD4+ and CD8+ T cells.[26-27] Research has shown that the CD4/CD8 ratio can also be used as a prognostic indicator in clinical settings. Studies have demonstrated that patients with a low CD4/CD8 ratio at the time of ART initiation are at greater risk of disease progression and have poorer overall survival rates compared to those with a higher ratio. This prognostic value underscores the importance of routine monitoring of the CD4/CD8 ratio in managing HIV-infected individuals and provides a basis for stratifying patients based on their immune status.[28-29] In addition to its role as a biomarker, the CD4/CD8 ratio has implications for therapeutic interventions aimed at restoring immune function. Strategies that effectively boost CD4+ T cell numbers, such as ART and immune-modulating therapies, can improve the CD4/CD8 ratio, promoting better immune health. Emerging approaches, including immune checkpoint inhibitors and therapeutic vaccines, also hold promise for rejuvenating CD8+ T cell function and restoring balance within the immune system.[30-31]

Mechanisms Influencing CD4/CD8 Ratios in Chronic HIV

The CD4/CD8 ratio in individuals with chronic HIV infection is influenced by a complex interplay of immunological and viral factors. Key factors that impact the CD4/CD8 ratio include viral load, immune activation, the presence of co-infections, and the efficacy of antiretroviral therapy (ART).

1. Viral Load: The level of HIV viral load is one of the most significant determinants of the CD4/CD8 ratio. High viral loads lead to increased immune activation and chronic inflammation, contributing to the accelerated depletion of CD4+ T cells. As the virus replicates, it targets CD4+ T cells for infection and destruction, leading to a progressive decline in their numbers. This depletion is often accompanied by a compensatory increase in CD8+ T cells, as the immune system attempts to control viral replication. Consequently, elevated viral loads are associated with lower CD4/CD8 ratios, indicating a state of immune dysregulation.[32-33]

2. Immune Activation: Chronic HIV infection induces a state of persistent immune activation, characterized by the ongoing stimulation of T cells, B cells, and other immune components. This activation can lead to the premature aging of CD4+ T cells and their subsequent depletion. The upregulation of activation markers, such as CD38 and HLA-DR, on both CD4+ and CD8+ T cells indicate a hyper-responsive immune state. This chronic immune activation not only contributes to the loss of CD4+ T cells but also leads to CD8+ T cell exhaustion, which manifests as a reduced ability of these cells to proliferate and produce effector cytokines. Therefore, the high levels of immune activation commonly observed in HIV-infected individuals significantly influence the CD4/CD8 ratio.[34-35]

3. Co-infections: The presence of co-infections, such as hepatitis viruses, cytomegalovirus (CMV), and tuberculosis, can further complicate the immune response in chronic HIV infection. These co-infections can exacerbate immune activation and contribute to additional CD4+ T cell depletion. For instance, CMV has been shown to drive the expansion of CD8+ T cells and contribute to their functional exhaustion, leading to a skewed CD4/CD8 ratio. Additionally, co-

infections can impact the effectiveness of ART, further complicating the immune landscape and influencing the CD4/CD8 balance.[36]

4. Antiretroviral Therapy (ART): The initiation and effectiveness of ART play a crucial role in modulating the CD4/CD8 ratio. Effective ART suppresses viral replication, leading to a reduction in immune activation and allowing for the recovery of CD4+ T cell numbers. Studies have demonstrated that individuals on effective ART typically exhibit higher CD4/CD8 ratios compared to those not receiving treatment. However, the degree of recovery may vary depending on factors such as the timing of ART initiation, the duration of HIV infection, and individual host factors. In some cases, individuals may still exhibit low CD4/CD8 ratios despite viral suppression, indicating ongoing immune dysregulation.[37-38]

5. Host Genetic Factors: Host genetic factors can also influence the CD4/CD8 ratio in chronic HIV infection. Genetic variations in immune-related genes, such as those encoding cytokines and immune receptors, can affect individual susceptibility to HIV infection, disease progression, and the overall immune response. For example, polymorphisms in genes involved in cytokine production can impact CD4+ T cell homeostasis and influence the balance between CD4+ and CD8+ T cells. Understanding these genetic factors may provide insights into why some individuals maintain healthier CD4/CD8 ratios and better immune resilience than others.[39]

6. Aging: Aging is another factor that can affect the CD4/CD8 ratio in individuals with chronic HIV. Older individuals often have a higher baseline level of immune senescence, characterized by a decline in CD4+ T cell function and an increase in CD8+ T cell numbers. This age-related immune decline may be exacerbated by the chronic inflammation and immune activation associated with HIV infection, further skewing the CD4/CD8 ratio.[40]

7. Lifestyle and Comorbidities: Lifestyle factors, including nutrition, physical activity, and psychosocial stressors, can also influence immune function and the CD4/CD8 ratio. Individuals with poor nutritional status may experience more pronounced immune dysfunction and CD4+ T cell depletion. Similarly, the presence of comorbidities, such as cardiovascular disease or metabolic syndrome, can exacerbate the immune dysregulation observed in chronic HIV infection, further impacting the CD4/CD8 balance.[41]

Prognostic Implications of CD4/CD8 Ratios

The CD4/CD8 ratio serves as a crucial prognostic indicator in the management of individuals living with chronic HIV infection. Variations in this ratio can provide valuable insights into the immune status of patients, their disease progression, and their response to antiretroviral therapy (ART).

1. Disease Progression: A low CD4/CD8 ratio is often associated with accelerated disease progression in HIV-infected individuals. Studies have shown that patients with lower ratios experience more rapid declines in CD4+ T cell counts and are at a higher risk of developing AIDS-

related complications. The relationship between a low CD4/CD8 ratio and disease progression can be attributed to the inadequate CD4+ T cell response to HIV, resulting in ineffective viral control and heightened immune dysfunction. Monitoring the CD4/CD8 ratio can thus aid clinicians in identifying patients at higher risk for rapid disease progression and implementing more aggressive treatment strategies.[42]

2. Immune Dysfunction and Comorbidities: The CD4/CD8 ratio not only reflects the state of the immune system but also correlates with the development of non-AIDS-related comorbidities. Individuals with low CD4/CD8 ratios are more susceptible to opportunistic infections, malignancies, and other chronic conditions, including cardiovascular disease and metabolic syndrome. This immune dysregulation can lead to increased morbidity and mortality, making the CD4/CD8 ratio a significant prognostic factor in the overall health and longevity of HIV-infected patients. By recognizing the implications of low CD4/CD8 ratios, healthcare providers can implement preventive measures and monitor for comorbid conditions more closely.[43]

3. Response to Antiretroviral Therapy: The CD4/CD8 ratio can also serve as a biomarker for assessing the effectiveness of ART. Patients who achieve viral suppression and exhibit an improvement in their CD4/CD8 ratio typically have better immune recovery and overall health outcomes. Conversely, those with persistently low ratios despite effective ART may be at risk for incomplete immune reconstitution, indicating potential issues with ART adherence, drug resistance, or ongoing immune activation. Regularly monitoring the CD4/CD8 ratio can thus guide clinical decisions regarding treatment modifications and interventions aimed at improving immune function.[44]

4. Long-Term Survival: Research has demonstrated that the CD4/CD8 ratio is associated with long-term survival in HIV-infected individuals. Patients with higher ratios tend to experience better survival rates compared to those with lower ratios. This correlation can be explained by the enhanced immune competence associated with favorable CD4/CD8 ratios, leading to better control of viral replication and reduced risk of opportunistic infections. The prognostic significance of the CD4/CD8 ratio highlights the importance of not only managing viral load but also fostering a balanced immune response.[45]

5. Potential for Personalized Treatment Strategies: Given the prognostic implications of CD4/CD8 ratios, there is potential for using this biomarker to develop personalized treatment strategies for individuals with chronic HIV infection. Tailoring therapeutic approaches based on a patient's CD4/CD8 ratio may help optimize immune recovery, improve overall health, and enhance the quality of life. For instance, patients with low ratios may benefit from intensified immune-modulating therapies or adjunctive interventions aimed at restoring CD4+ T cell populations and mitigating chronic inflammation.[46]

Therapeutic Strategies to Enhance CD4/CD8 Ratios

Enhancing the CD4/CD8 ratio in individuals living with chronic HIV infection is critical for improving immune function and overall health outcomes. Several therapeutic strategies aim to restore the balance between CD4+ and CD8+ T cells, reduce immune activation, and promote immune resilience. Here are some of the promising approaches currently being explored:

1. Antiretroviral Therapy (ART): The cornerstone of HIV management, ART, plays a crucial role in improving CD4/CD8 ratios by suppressing viral replication. Effective ART reduces the viral load, which in turn decreases immune activation and allows for the recovery of CD4+ T cells. Early initiation of ART has been associated with better immune reconstitution and higher CD4/CD8 ratios. Continuous monitoring of CD4 counts and the CD4/CD8 ratio is essential to assess the effectiveness of ART and make necessary adjustments to treatment regimens.[47]

2. Immune Checkpoint Inhibitors: Immune checkpoint inhibitors, which are primarily used in cancer therapy, have shown potential in modulating immune responses in HIV-infected individuals. These agents, such as anti-PD-1 and anti-CTLA-4 antibodies, can enhance the functionality of exhausted CD8+ T cells and promote CD4+ T cell recovery. By targeting inhibitory pathways, these therapies may help restore the balance between CD4+ and CD8+ T cells, improving the overall immune response against HIV.[48]

3. Cytokine Therapy: Cytokine therapy aims to modulate the immune response by enhancing the production and function of key cytokines involved in T cell proliferation and differentiation. Interleukin-2 (IL-2) has been explored as a potential therapy to boost CD4+ T cell counts in HIV-infected individuals. However, the efficacy of IL-2 in improving clinical outcomes has been variable, and its use is often limited due to associated toxicities. Ongoing research is focusing on optimizing cytokine therapy by identifying specific cytokines or combinations that can effectively enhance the CD4/CD8 ratio without adverse effects.[49]

4. Immune Modulators: Agents that modulate the immune system, such as Toll-like receptor (TLR) agonists, may enhance immune responses in HIV-infected individuals. These agents can stimulate innate immune responses, leading to increased activation and proliferation of CD4+ and CD8+ T cells. TLR agonists have shown promise in preclinical and early-phase clinical studies, suggesting their potential to improve CD4/CD8 ratios and overall immune function.

5. Co-infection Management: Co-infections, such as hepatitis C virus (HCV) or cytomegalovirus (CMV), can exacerbate immune activation and impact CD4/CD8 ratios. Effectively managing these co-infections through appropriate antiviral therapies can help reduce immune dysregulation and promote a healthier CD4/CD8 balance. Regular screening and treatment of co-infections should be integrated into the care of individuals living with HIV to optimize immune health.[50]

6. Lifestyle Interventions: Non-pharmacological strategies, including lifestyle modifications, can play a role in enhancing immune resilience and improving CD4/CD8 ratios. Encouraging a balanced diet rich in antioxidants, regular physical activity, stress reduction techniques, and smoking cessation can positively influence immune function. Studies suggest that healthier

lifestyle choices may lead to improved immune parameters, including the CD4/CD8 ratio, and contribute to better overall health outcomes in HIV-infected individuals.

Conclusion

The CD4/CD8 ratio serves as a vital biomarker of immune resilience in individuals living with chronic HIV infection. This ratio not only reflects the balance between CD4+ and CD8+ T cells but also provides insights into immune status, disease progression, and the effectiveness of therapeutic interventions. Therapeutic strategies to enhance CD4/CD8 ratios encompass a wide range of approaches, including effective antiretroviral therapy, immune checkpoint inhibitors, cytokine therapy, and immune modulation. Additionally, lifestyle interventions and the management of co-infections are crucial in promoting immune resilience and restoring the balance between CD4+ and CD8+ T cells.

References

1. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
2. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
3. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
4. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
5. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
6. Giraldo NA, Bolaños NI, Cuellar A, Guzman F, Uribe AM, Bedoya A, Olaya N, Cucunubá ZM, Roa N, Rosas F, Velasco V. Increased CD4+/CD8+ double-positive T cells in chronic Chagasic patients. PLoS neglected tropical diseases. 2011;5(8): e1294.
7. Jones RB, Walker BD. HIV-specific CD8+ T cells and HIV eradication. The Journal of clinical investigation. 2016;126(2):455-463.
8. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.
9. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
10. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
11. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
12. Obeagu EI, Obeagu GU. CD4/CD8 Ratios: The Immunological Barometer in HIV. Elite Journal of Laboratory Medicine. 2024;2(2):8-20.

Citation: Obeagu EI, Akinleye CA, Edoho SH. Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV. Elite Journal of Medicine, 2024; 2(10): 1-11

13. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024 Mar 1;103(9):e37354.
14. Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD. CD4: CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus–infected patients on antiretroviral therapy: the Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases. 2017;65(6):959-966.
15. Falutz J, Kirkland S, Guaraldi G. Geriatric syndromes in people living with HIV associated with ageing and increasing comorbidities: implications for neurocognitive complications of HIV infection. InNeurocognitive Complications of HIV-Infection: Neuropathogenesis to Implications for Clinical Practice 2020: 301-327.
16. Avelino-Silva VI, Miyaji KT, Mathias A, Costa DA, de Carvalho Dias JZ, Lima SB, Simoes M, Freire MS, Caiaffa-Filho HH, Hong MA, Lopes MH. CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016;71(2):189-195.
17. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
20. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
21. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
22. Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD. CD4: CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus–infected patients on antiretroviral therapy: the Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases. 2017;65(6):959-966.
23. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
24. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7):16-24
25. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine. 2024;2(9):1-9.
26. Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4: CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically

suppressed HIV-positive patients. African Journal of Reproduction and Gynaecological Endoscopy. 2015;18(1).

27. Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB. Predictors of CD4: CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PloS one. 2013;8(10): e77665.
28. Moysi E, Del Rio Estrada PM, Torres-Ruiz F, Reyes-Terán G, Koup RA, Petrovas C. In situ characterization of human lymphoid tissue immune cells by multispectral confocal imaging and quantitative image analysis; implications for HIV reservoir characterization. Frontiers in Immunology. 2021; 12:683396.
29. Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G. Determinants of a low CD4/CD8 ratio in HIV-1–infected individuals despite long-term viral suppression. Clinical Infectious Diseases. 2016;62(10):1297-1303.
30. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proceedings of the National Academy of Sciences. 2008;105(50):19851-19856.
31. Sainz T, Serrano-Villar S, Díaz L, Tomé MI, Gurbindo MD, de José MI, Mellado MJ, Ramos JT, Zamora J, Moreno S, Muñoz-Fernández MÁ. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. Aids. 2013;27(9):1513-1516.
32. Fang RH, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. Aids. 2008;22(2):171-184.
33. Obeagu EI, Obeagu GU. CD4/CD8 Ratios: The Immunological Barometer in HIV. Elite Journal of Laboratory Medicine. 2024;2(2):8-20.
34. Bordoni V, Brando B, Piselli P, Forini O, Perna FE, Atripaldi U, Carputo S, Garziano F, Trento E, D'Agosto G, Latini A. Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: a multicenter study. PLoS One. 2019;14(12): e0225415.
35. Wolday D, Legesse D, Kebede Y, Siraj DS, McBride JA, Striker R. Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia. PLoS One. 2020;15(10): e0240880.
36. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
37. Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, Espinosa N, Viciana P, López-Cortés LF. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. PLoS One. 2018;13(10): e0205777.
38. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+

T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS pathogens. 2014;10(5): e1004078.
39. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopycinski J, Deymier MJ, Vanderford TH, Nganou-Makamdop K, Ende Z. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proceedings of the National Academy of Sciences. 2015;112(12): E1480-1489.
40. Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG, Bosch RJ. Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine. 2022;80.
41. Aldrete S, Jang JH, Easley KA, Okulicz J, Dai T, Chen YN, Pino M, Agan BK, Maves RC, Paiardini M, Marconi VC. CD4 rate of increase is preferred to CD4 threshold for predicting outcomes among virologically suppressed HIV-infected adults on antiretroviral therapy. PloS one. 2020;15(1): e0227124.
42. Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sighem A, de Wolf F, Hallett TB. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. The Lancet infectious diseases. 2015;15(7):810-818.
43. Caterino-de-Araujo A, Campos KR, Oliveira LM, Rigato PO. Biomarkers in a Cohort of HIV-Infected Patients Single-or Co-Infected with HTLV-1, HTLV-2, and/or HCV: A Cross-Sectional, Observational Study. Viruses. 2022;14(9):1955.
44. Dock JN, Effros RB. Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. Aging and disease. 2011 Oct;2(5):382.
45. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2014;69(7):833-842.
46. Passos DF, Bremm JM, da Silveira LL, Jantsch MH, da Silva JL, Disconzi E, Rezer JF, Schwarzbold AV, Marques AC, Schetinger MR, Leal DB. CD4/CD8 ratio, comorbidities, and aging in treated HIV infected individuals on viral suppression. Journal of Medical Virology. 2020;92(12):3254-3264.
47. Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M, DeSalvador F, Harvey-Langton A, Dunais B, Laffon M, Cottalorda J. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. Journal of neurovirology. 2017; 23:216-225.
48. Guaraldi G, Milic J. The interplay between frailty and intrinsic capacity in aging and HIV infection. AIDS Research and Human Retroviruses. 2019;35(11-12):1013-1022.
49. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for immunotherapy of cancer. 2016; 4:1-25.
50. Obeagu EI, Obeagu GU. Immunological Currency: Evaluating CD4/CD8 Ratios in HIV. Elite Journal of Immunology. 2024;2(3):19-32.

Citation: Obeagu EI, Akinleye CA, Edoho SH. Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV. Elite Journal of Medicine, 2024; 2(10): 1-11

Citation: Obeagu EI, Akinleye CA, Edoho SH. Immune Resilience: Insights from CD4/CD8 Ratios in Chronic HIV. Elite Journal of Medicine, 2024; 2(10): 1-11